Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

[Practical Pharmaceutical Researches Utilizing Clock Genes].

Ushijima K.

Clinical Trial on Systemic / IV, published in Yakugaku Zasshi (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Yakugaku Zasshi (2026)
Country
Japan
Reported sample size
—
Source database
PubMed
PMID
41485963
DOI
10.1248/yakushi.25-00125

Abstract (original English)

The biological clock system regulates gene transcription in approximately 24 h cycles, creating circadian rhythms with respect to drug pharmacokinetics and pharmacological efficacy. My research focuses on clinical applications of clock systems and the elucidation of pathophysiological mechanisms involving clock genes. In the present study, I aimed to identify the optimal timing of methylprednisolone (mPSL) administration to pediatric patients undergoing liver transplantation. A randomized clinical trial of 60 such patients demonstrated that evening administration (20:00) was associated with significantly fewer episodes of acute rejection and lower histological damage scores than morning administration (08:00). Notably, in patients who were not undergoing pretreatment with rituximab, mPSL administration in the evening completely prevented acute rejection within 14 d of transplantation. Pathophysiological studies revealed low clock gene expression rhythms in the adipose tissue of obese diabetic (ob/ob) mice, mediated through low histone H3K9 acetylation of the Dbp gene. Pharmacological correction of the abnormal histone acetylation increased the circulating adiponectin concentration and insulin sensitivity through peroxisome proliferator-activated receptor (PPAR)-γ mediated adipocyte differentiation. Importantly, low Dbp and PPAR-γ expression was also identified in human omental

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansAnimalsCircadian ClocksMicroRNAsCircadian RhythmPPAR gammaGraft RejectionMiceCLOCK ProteinsHistones

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research